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Abstract: Previously described methods for the combined analysis of common and rare  variants 
have disadvantages such as requiring an arbitrary classification of variants or permutation 
testing to assess statistical significance. Here we propose a novel method which implements a 
weighting scheme based on allele frequencies observed in both cases and controls. Because the 
test is unbiased, scores can be analyzed with a standard t-test. To test its validity we applied it 
to data for common, rare, and very rare variants simulated under the null hypothesis. To test its 
power we applied it to simulated data in which association was present, including data using 
the observed allele frequencies of common and rare variants in NOD2 previously reported in 
cases of Crohn’s disease and controls. The method produced results that conformed well to 
those expected under the null hypothesis. It demonstrated more power to detect association 
when rare and common variants were analyzed jointly, the power further increasing when rare 
variants were assigned higher weights. 20,000 analyses of a gene containing 62 variants could 
be performed in 80 minutes on a laptop. This approach shows promise for the analysis of data 
currently emerging from genome wide sequencing studies.
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Introduction
As has previously been pointed out, there are obvious merits for combining informa-
tion from different variants within a gene when considering whether there is in gen-
eral, evidence that the gene influences a particular phenotype. Considering variants 
jointly models the biological reality that a number of different variants may separately 
impact the functioning of a gene. In addition, in the context of whole genome analy-
ses, consideration of variation at the level of a gene reduces the problem of multiple 
testing, from having to deal with hundreds of thousands of variants, to having to deal 
with twenty thousand genes. However, a gene may contain common and rare variants 
that both affect phenotype but need to be dealt with in different ways. The combined 
affects of common variants can be dealt with by approaches that incorporate informa-
tion obtained by analyzing individual variants, for example by utilizing the associated 
P-values.1,2 However, such methods are not applicable to very rare variants or those 
only observed once or twice in a sample. Methods to deal with such rare variants have 
previously been discussed,3,4 and may consist simply of a comparison between the 
combined counts of all rare variants observed in cases and controls.5 This approach 
however, is limited in that difficulty may lie in the classification of a variant as “rare”, 
as common variants cannot be utilized, their much larger allele counts tending to 
swamp the signal from rare variants.
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A more attractive approach is to utilize information 
jointly from both common and rare variants. One method of 
doing this, termed the combined multivariate and collapsing 
method, uses both the above approaches simultaneously to 
provide an overall test for association at the level of a gene.2 
A possible criticism of this approach is that variants with dif-
ferent allele frequencies need to be differentially classified so 
they can be subjected to different methods of analysis. Once 
again, it is not clear what criteria should be used to define a 
variant as “rare.” A previously described method that avoids 
having to treat common and rare variants as qualitatively dif-
ferent involves introducing a weighting scheme that accords 
more weight to rare variants, but which nevertheless incorpo-
rates information from all variants in a unified analysis. One 
can assign a weight to each variant, and for each subject one 
can then produce an overall score consisting of the sum of 
the allele counts for each variant multiplied by its weight.6,9 
Thus, for each variant i the weight, w
i
, is given by:
w n q qi i i i= −( )1 , where q m ni i
U
i
U= + +1 2 2/ .
Here, mi
U  is the number of mutant alleles observed for 
variant i in unaffected subjects, ni
U  is the number of unaffected 
subjects genotyped for variant I, and n
i
 is the total number of 
affected and unaffected subjects genotyped for variant i. We 
define an indicator variable I
ij
 which takes values of zero, one 
or two according to the number of mutant alleles of variant i 
in subject j. The genetic score for subject j is then given by:
 g I wj ij ii
L
=
=∑ /1 . 
These genetic scores can be compared between cases and 
controls in order to test the hypothesis that the gene is associ-
ated with the disease. As the distribution of these scores under 
the null hypothesis is unknown, the authors recommended 
a permutation test based on the ranks of these scores, and 
have stated that this could be completed for 20,000 genes, 
each with 50 polymorphic loci, in a sample of 1000 cases 
and 1000 controls in 600 hours.
It can be argued, however, that, although attractive in prin-
ciple, the approach as described has a number of drawbacks. 
One problem is that the weight accorded to each variant differs 
markedly with different sample sizes. In order to better under-
stand this effect and how it occurs, we can define a measure 
r
q
 as the ratio of the weight, w, accorded to a variant with 
equal allele frequencies (minor allele frequency [MAF] = 0.5) 
relative to the weight for a variant with MAF, q. As the 
analysis will depend on the relative rather than the absolute 
values of weights, r is a useful measure to better understand 
the performance of the method. It also defines the relative 
contribution to the genetic score of each allele observed, with 
the contribution of an allele with MAF = 0.5 being taken to 
be one. If all variants are genotyped in the same number of 
subjects (so that n
i
 is constant), then r is given by:
 r q q= −1 1 2/ ( )/ .
If we define a “very rare” variant as one that is not 
observed at all in controls, then the method as described will 
estimate q as 1/(2nU + 2). For samples with equal numbers of 
cases and controls (so that n
i
 = 2ni
U), then for such very rare 
variants r will equal 7.1 for a sample size of 100 controls, 
22.4 for a sample size of 1000, and 70.7 for a sample size of 
10,000. The fact that the weights assigned are dependent on 
sample sizes would mean that studies of the same gene would 
not be directly comparable across different datasets.
A more critical problem is that there is an intrinsic bias in 
this approach as the estimated frequency of the variant is only 
based on observations in control subjects. The rationale for 
doing this is that one seeks to estimate the frequency of the 
variant in the general population, without artificially inflat-
ing the frequency by taking information from cases in which 
the frequency of a disease causing variant may be higher. In 
practice this inevitably introduces a bias into the procedure. 
This phenomenon has been discussed elsewhere in more 
general terms.7 In the present context, it means that variants 
which occur in cases but not controls will be weighted more 
highly than variants which occur only in controls.  Specifically, 
a variant observed once in cases but not in controls will make 
a contribution to the score that is 2  = 1.41 greater than a 
variant observed once in controls but not in cases. As the 
value for r falls as q increases, and, because q is calculated 
from the number of alleles observed in controls, a variant 
observed twice in cases but not in controls makes a contribu-
tion which is 3  = 1.73 greater than that of a variant observed 
twice in controls but not in cases. This asymmetrical nature 
of the analysis is the prime reason why it is necessary to use 
a permutation test to evaluate the significance of the results.
It might be thought that a simple way to avoid this bias 
would be to base allele frequency estimates on both cases and 
controls rather than just on cases. However, this then creates a 
different problem in that the weight is extremely sensitive to 
the estimated allele frequency. The relative weight assigned 
according to allele frequency is illustrated in Figure 1. This 
shows how the allocated weight falls dramatically as the 
frequency increases from zero. We can envisage a scenario 
whereby a very rare variant occurs only in cases. If we  estimate 
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the MAF as q = m/2n (where m is the allele count in both cases 
and controls and n is the number of cases and controls), then 
obviously if we observe the variant twice amongst cases rather 
than once, we will double the estimate of q. If we use these 
observations to produce a value for w, then the relative weight, 
r, for a variant observed 4 times is approximately half that 
for a variant observed only once. If we consider two variants 
which  are seen only amongst cases then the contribution made 
to the overall genetic score for the sample made by a variant 
that occurs 4 times will only be twice that of the contribution 
of a variant that only occurs once. For a variant occurring 10 
times in cases and never in controls, its overall contribution 
is only 3.2 times that of a variant that only occurs once. This 
loss of information would be expected to reduce the power of 
the analysis to detect the effects of rare variants.
The previously proposed weighting scheme generates 
weights that are sensitive to sample size and that produce 
genetic scores that can only be analyzed using permutation 
testing. Here we propose and evaluate an alternative weight-
ing scheme that can produce score statistics with a known null 
hypothesis distribution. This means that analysis can be very 
rapid relative to permutation testing. Additional advantages of 
the approach we propose include weights that do not vary mark-
edly according to sample size and that the user can readily tune 
the weights which are allocated by using a weighting factor that 
can be adjusted as appropriate for the dataset being analyzed.
Methods
The method of analysis we propose utilizes a novel weight-
ing scheme that incorporates a weighting factor, f. Using the 
allele frequency q
i















,   
we assign a weight W
i
  according to this formula:
W
i





This is the equation for a parabola with a minimum value 
of 1 at q = 0.5, which intercepts the y-axis at f when q = 0. 
(To make the approach easier to understand, we define W 
so that it increases with rarer variants. This means it can 
be used as a multiplier for contributions to the score rather 
than a divider as w was.) Figure 2 illustrates this weighting 
function for a value of f = 20, showing that allocated weights 
fall more gradually with the parabolic function than for 
the approximately inverse square root function previously 
used. Using different values of f allows the relative weight 
assigned to rare variants to be varied. If f = 1 is used, then all 
variants are weighted equally. This will mean that common 
variants occurring frequently will tend to contribute the most 
information. On the other hand, if a large value is used such 
as f = 1000, rare variants will be accorded far more weight 
and common variants will be relatively ignored. If for some 
reason one wished to ignore contributions from very rare 
variants, then one could set f = 0.
Similar to the previous approach, a genetic score is 
calculated for each subject j, as the sum of the products of the 
allele count for each variant multiplied by its weight, W
i
:













Figure 1 Plot of the relative weight, r, using the originally proposed weighting scheme 
accorded to each allele of a variant with frequency q for sample size n = 2000. 
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Figure 2 Plot of the weight, W, using the novel weighting scheme accorded to each 
allele of a variant with frequency q and weighting factor f = 20.
Note: The value of W at q = 0.5 is 1. 
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The scores for a set of cases and controls can then be 
 compared with a standard two-sample t-test. The test is 
one-tailed because it tests the hypothesis that the allele with 
a lower frequency at each variant tends to be found more 
commonly amongst cases than controls. This test is expected 
to be valid as there is no asymmetry in the way cases and 
controls are treated, hence the test should be unbiased.
In order to demonstrate the validity of this approach, 
it was applied to simulated datasets containing variants of 
different frequencies: a common variant with MAF = 0.45, 
a rare variant with MAF = 0.01, and a combined set of 
20 very rare variants each with MAF = 0.0005 analyzed 
together. A sample size of 1000 cases and 1000 controls 
was used and 10,000,000 simulations were carried out for 
each dataset. Each type of variant was analyzed separately 
and then all three were analyzed jointly. For the individual 
analyses the weighting was irrelevant, but for the joint 
analysis different weighting factors of 1, 10, 100, and 
1000 were used.
In order to make some assessment of the power of the 
approach it was applied to datasets simulated with different 
values for the MAF in cases and controls. For the common 
variant, values of 0.5 and 0.45 were used, for the rare variant 
0.015 and 0.05, and for the very rare variants 0.00025 and 
0.000025. These values were chosen so that each type of vari-
ant would produce a similar P value if analyzed separately. 
Again, a sample size of 1000 cases and 1000 controls was 
used, with variants analyzed individually and jointly with dif-
ferent weighting factors. For each dataset, 1000 simulations 
were performed. The proportion of simulations achieving 
critical P-values of 10–3, 10–4, 10–5 and 10–6 was measured 
and the average -log(p) was calculated.
The method was also applied to a dataset based on a 
published study of NOD2 (previously named CARD15), in 
which all variants were identified in a sample of 453 subjects 
with Crohn’s disease and 103 controls.8 This study identified 
nine common variants (MAF . 5%) along with 53 rare vari-
ants which were observed in cases, controls, or both. Again, 
1000 simulations were performed to produce sample datasets 
that were generated using the observed allele frequencies. 
The simulations were carried out conditional on the observed 
allele frequencies and assuming independence between the 
loci. The new method was applied to each common variant 
individually, all common variants jointly, all rare variants 
jointly, and finally all variants in a combined analysis with 
a range of weighting factors.
In order to gain an assessment of how long the method 
would take to perform on genome wide data, 20,000  analyses 
were performed on the combined set of all 62 NOD2 
variants.
Results
The Q-Q plots for the expected versus observed values for 
-log(p) are shown in Figure 3 for the common and rare 
variants considered independently and very rare variants 
analyzed together. These plots show that the method is valid 
and conforms fairly well with the expected distribution. The 
method is mildly anticonservative for small P-values when 
applied to the common variant. This may reflect the discrete 
nature of the data, as each subject will have a relative score 
of 0, 1, or 2 rather than a continuously distributed trait as 
expected by the t-test. The test is somewhat conservative for 
small P-values when applied to rare variants, which is likely 
due to the small total number of variant alleles. This means 
that the datasets are somewhat under-powered to achieve 
highly significant results. Figure 4 shows the Q-Q plots when 
applied to combined analyses of all loci with different values 
for the weighting factor, f. These show that when variants 
with different weights contribute to the scores, then the 
method conforms well to the expected distribution.
The power for the test to produce critical P-values is 
shown in Table 1 along with the mean values for -log(p). 
This shows that the common, rare, and very rare variants 
when considered separately produce average -log(p) values 
of 3.28, 3.28, and 3.04, respectively. If they are included in 
a combined analysis with a weighting factor of 1, so that 
allele counts of all variants are simply added together, an 
average -log(p) of 4.74 is obtained with a power of 0.22 to 
achieve a P-value of 10–6. However, if the weighting factor 
is increased to 10, then the average -log(p) increases to 
7.08 and the power to achieve a P-value of 10–6 increases to 
0.69. Larger values for the weighting factor of 100 or 1000 
resulted in reduced power although still exceeding that for 
the unweighted analysis. Figure 5 shows the graph of aver-
age -log(p) against different values for the weighting factor. 
It can be seen that the maximum power occurs with weight-
ing factors somewhat less than 10. In fact, the maximum 
average -log(p) of 7.29 is obtained with f = 6.3.
The P-values obtained when the method is applied to 
real data are shown in Table 2. Six of the nine common 
variants each produced evidence in favor of association with 
average -log(p) values ranging from 2.19 to 4.36. When all 
common variants were analyzed together they produced an 
average -log(p) of 4.84. The 53 rare variants produced only 
modest evidence for association and when analyzed together 
produced an average -log(p) of 2.20. When the common and 





Advances and Applications in Bioinformatics and Chemistry 2012:5
rare variants were all included in an unweighted analysis 
they produced a stronger evidence for association with an 
average -log(p) of 5.78. Changing the weighting factor, f, 
to 10 resulted in a higher average -log(p) of 6.37. Using 
this weighting factor produced some increase in power at all 
P-values, and the power to obtain a P-value of 10–6 increased 
from 0.42 to 0.57. Using higher values for the weighting 
factor resulted in diminished power, similar to that for the 
unweighted analysis. Figure 6 shows the graph of average 
-log(p) against different values for the weighting factor and 
shows that the maximum average -log(p) of 7.01 is obtained 
with f = 2.5.
The time taken to carry out 20,000 analyses of repeated 
simulations from the real data incorporating all 62 variants 
was 80 minutes on a Windows laptop with a 2.4 GHz Intel 
Core i7 processor.
Discussion
The proposed method of analysis applies a standard two-
sample t-test to genetic scores obtained from allele counts of 
variants weighted according to their observed frequency in 
both cases and controls. This avoids the need for permutation 
testing and allows for rapid analysis. Simulation studies con-
firm that the method is valid and demonstrate that combining 
information from both common and rare variants can, in at 
least some situations, provide more power than considering 
each separately. Furthermore, it confirms that weighting the 
scores from different variants can further increase power. 
The use of a smooth weighting function means that all types 
of variants are subjected to the same method of analysis. 
A weighting factor allows the user to choose a weighting 
scheme appropriate for the type of trait being studied.
Of course, as pointed out previously,6 a variety of differ-
ent functions could be used to generate weights. We have 
chosen a parabolic function that can easily be adjusted and 
that produces weights relative to a value of one for variants 
with MAF = 0.5. It is possible, however, that more or less 
sharply curved functions or sigmoid functions might offer 
some advantages. Most importantly, we are of the opinion 
that cases and controls should be treated equally to avoid the 
need for simulation, and that the function should not fall off 
too sharply with very small values of MAF.
It is easy to speculate that different values for the weight-
ing factor might be appropriate for different situations. A high 
value, which gave more weight to very rare variants, might 
be helpful for a disease that appeared often to result from 
mutations with large effect size, typically a rare disease with 































Figure 3 Q-Q plot of -log(α) against -log(β). (A) Common variant (MAF = 0.45). 
(B) Rare variant (MAF = 0.01). (C) 20 very rare variants analyzed together (each 
with MAF = 0.0005). 
Abbreviations: MAF, minor allele frequency; α, target P-value; β, the proportion 
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a common syndrome that might be expected to arise from 
the cumulative effects of common variants could be more 
appropriately analyzed with a relatively low value, although of 
course rare variants might still exert important effects. As the 
analyses are quick to perform, it might be reasonable to analyze 
datasets using a number of different values for the weighting 
factor, provided that appropriate corrections are then made for 
multiple testing. The different results obtained using different 
weighting factors might then allow one to make some infer-
ences about the nature of the effects influencing susceptibility 
to the trait in terms of the relative contribution of common and 
rare variants in the gene under consideration.
The method described clearly assumes some kind of 
additive contribution from different variants; however, it is 
unclear how well it would perform with variants with reces-
sive effects. It might be possible, in principle, to devise some 
kind of alternative weighting scheme aimed specifically to 
detect associations using a recessive model.
In contrast to some approaches, no special treatment 
is required to deal with linkage disequilibrium (LD) 
Figure 4 Q-Q plot of -log(α) against -log(β). (A) Weighting factor f = 1. (B) Weighting factor f = 10. (C) Weighting factor f = 100. (D) Weighting factor f = 1000. 
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to the score might tend to overshadow contributions from 
individual variants. In such situations, it might be beneficial 
to identify this and in some way scale down the weights of 
variants belonging to such LD groups.
As was also noted for the previously described method,6 
this implementation implicitly assumes that it is the rare allele 
of each variant that may be associated with the disease. This 
allows the effects of different variants to be combined within 
an individual and also implies that significance testing can 
be one-sided. This assumption may be reasonable for rare 
variants when the phenotype being studied reduces fitness. 
However, the method as it stands could not be applied to a 
quantitative trait in which there was no a priori assumption 
as to the direction of effect of each allele.
There are both biological and statistical arguments in 
favor of considering the alternative hypothesis to be that in 
general it is the rarer allele of each variant that is associated 
with disease. The biological argument is that if one begins 
with the reference sequence and then generates a variant at 
random, then one is more likely to produce a disease than 
to prevent one. Additionally, if a randomly generated vari-
ant should happen to be beneficial and to confer a survival 
advantage, then, over time, selection pressures will increase 
its frequency until it ultimately becomes common. Thus, one 
may expect that, on average, rare variants will be more likely 
to be associated with deleterious phenotypes. There is also 
a statistical argument for basing the test on the assumption 
that rare variants will be more likely to show association 
with a rare phenotype, even if it is nondeleterious or even 
advantageous. To begin with an example, suppose that a 
particular phenotype has prevalence 0.01 and that a variant 
with allele frequency 0.001 in the population produces a 
ten-fold increase in risk of manifesting this rare phenotype. 
It is simple to calculate that in samples of cases with this 
phenotype and of controls, we would expect allele frequen-
cies of 0.0099 and 0.00091, respectively. With a sample size 
Table 1 Power of score analysis to detect association using different datasets and weighting factors
Variants used MAF Power to achieve target P-value Mean -log(p)
Controls Cases P , 0.001 P , 0.0001 P , 0.00001 P , 0.000001
Common 0.45 0.5 0.54 0.30 0.14 0.06 3.28
Rare 0.005 0.015 0.54 0.30 0.12 0.04 3.28
20 very rare variants 0.000025 0.00025 0.50 0.11 0.01 0.00 3.04
Combined, f = 1 0.83 0.63 0.40 0.22 4.74
Combined, f = 10 0.99 0.94 0.83 0.69 7.08
Combined, f = 100 0.92 0.77 0.57 0.36 5.40
Combined, f = 1000 0.9 0.73 0.52 0.30 5.15
Note: Sample size consists of 1000 cases and 1000 controls. 




















Figure 5 Plot of the mean -log(p) value obtained for different values of the weighting 
factor, f, when applied to combined analysis of all variants in simulated datasets of 
1000 cases and 1000 controls.
between variants. If this is present it is not expected to affect 
the  validity of the test. In essence this is because all informa-
tion is combined at the level of the individual subject before 
being entered into the analysis. Hence, if there is nonindepen-
dence of genotypes within a subject, the fact that observations 
for different subjects are independent of each other is not 
affected. And so, the total scores are still expected to follow 
a random distribution under the null hypothesis. To illustrate 
this, we could consider the situation in which two variants are 
in complete LD with each other. This would be equivalent 
to having information from just one variant, but counting it 
twice for each subject, which would have exactly the same 
effect as assigning twice the weight to that variant. Thus, 
LD relationships can be seen as having equivalent effects to 
varying the weights assigned to variants. As such, they would 
not influence the validity of the analysis in the sense that they 
would not impact on the number of statistically significant 
results expected to occur by chance. They might, however, 
have an effect on power. If a large number of common vari-
ants were in LD with each other, then their contributions 
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of 500 of each we might expect to observe the variant in ten 
cases and one control. Now, suppose that we have a different 
variant also with frequency 0.001 but which is “protective” 
so that it produces a relative risk (RR) of 0.1 rather than ten. 
In this situation, we calculate the expected allele frequencies 
in cases and controls to be 0.0001 and 0.001. With the same 
sample size we might observe the variant once amongst the 
controls and not at all in the cases. Thus, the excess of the 
rare variant associated with the rare phenotype amongst 
subjects with the rare phenotype, is larger than the excess 
of the rare variant associated with the common phenotype 
observed amongst subjects with the common phenotype. If 
we were to count up both variants together we would still 
expect to find an overall excess of rare alleles amongst sub-
jects with the rare phenotype in spite of the fact that both 
variants produce an equal and opposite effect on risk. This 
particular example represents just one instance of a general 
phenomenon, which is that if one assumes an equal and oppo-
site effect on risk of a pair of variants with equal frequency, 
then there will be more enrichment of the “risk” variant 
amongst “cases” than there is enrichment of the “protective” 
variant amongst “controls.” This statistical effect continues 
to be active as the MAF of the variants increases. At higher 
values for the MAF, an additional complication occurs: the 
rarer allele becomes so enriched amongst cases that when the 
frequency is jointly estimated from cases and controls, this 
allele actually becomes designated as the “common” allele, 
in spite of the fact that in the population as a whole it is rarer. 
That is, the allele that is rarer in the population becomes the 
allele that is more common in the case control sample. Even 
taking this phenomenon into account, for pairs of variants 
with RR equal to 10 or 0.1, one still expects to observe an 
excess of more rare alleles amongst cases with true values of 
MAF up to 0.24. For values of RR of 2 and 0.5, one expects 
an overall excess of rare alleles for all values of MAF up to 
0.42; and for values of RR of 1.5 and 0.7, one expects this 
up to values of MAF of 0.45. Thus, when variants within a 
gene affect risk there is a consistent phenomenon that means 
that, over a wide a range of genetic models, one expects to 
observe an overall excess of rare alleles amongst subjects 
Table 2 Power of score analysis to detect association using different datasets and weighting factors using variant counts generated 
from those observed in NOD28
Variants used MAF Power to achieve target P-value Mean -log(p)
Controls Cases P , 0.001 P , 0.0001 P , 0.00001 P , 0.000001
Common variants
 5′ UTR-33 g→T 0.330 0.419 0.21 0.08 0.02 0.01 2.19
 534 C→g 0.383 0.309 0 0 0 0 0.04
 802 C→T 0.277 0.414 0.73 0.48 0.28 0.12 4.09
 1377 C→T 0.286 0.418 0.67 0.41 0.20 0.09 3.80
 1761 T→g 0.403 0.332 0 0 0 0 0.05
 2104 C→T 0.044 0.108 0.39 0.11 0.01 0 2.76
 2722 g→C 0.010 0.061 0.47 0.06 0 0 2.94
 2863 g→A 0.102 0.070 0 0 0 0 0.08
 3020insC 0.019 0.106 0.92 0.62 0.25 0.06 4.36
Nine common variants 0.86 0.65 0.43 0.25 4.84
53 rare variants 0.20 0.04 0 0 2.20
Combined, f = 1 0.94 0.83 0.64 0.42 5.78
Combined, f = 10 0.98 0.91 0.77 0.57 6.37
Combined, f = 100 0.96 0.85 0.67 0.44 5.77
Combined, f = 1000 0.96 0.84 0.65 0.41 5.69
Note: Sample size consists of 453 cases and 103 controls.




















Figure 6 Plot of the mean -log(p) value obtained for different values of the weighting 
factor, f, when applied to combined analysis using variant counts generated from 
those observed in NOD2. 
Note: Sample size consists of 453 cases and 103 controls.
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having a rare phenotype. This statistical effect applies even 
before one considers the biological argument that one expects 
rare variants, a priori, to be deleterious.
It was also noted previously6,9 that weighting could be 
based not on allele frequency, but on the presumed effect of 
the variant on gene function. This could be equally incorpo-
rated into the score test as we describe it, the only additional 
feature being that we would suggest that the t-test be used 
for significance testing rather than permutation, provided 
that cases and controls were treated symmetrically. A further 
possibility would be to produce a combined weight based 
on both allele frequency and presumed effect. One simple 
approach would be to simply multiply the weight based on 
effect by the weight derived from frequency. Such techniques 
could mean that for example, a rare variant producing a 
nonsynonymous coding change would be assigned a higher 
weight than either a common nonsynonymous variant or a 
rare synonymous variant.
Tests such as these can be applied at the level of a single 
gene, a region within a gene, or a set of genes comprising a 
pathway. It is up to the user to define the region of interest and 
to make decisions about such matters as to whether or not to 
include intergenic variants and intronic variants, whether to 
focus on a particular transcript or particular exon, and what 
assumptions to make about how to define regulatory regions. 
Sometimes the same variant will be defined to be included 
in the analysis of two or more different genes but this does 
not pose any particular problem for the method.
Which functions and/or weighting schemes in fact pro-
duce the best performance when applied to real data can only 
be properly assessed when more such data becomes available 
for analysis. As such data emerges over the next few years 
it will be helpful to undertake a formal comparison of dif-
ferent approaches. For now, it seems reasonable to suggest 
that a weighting factor of around 10 might be appropriate 
for analyses of diseases in which it is suspected that both 
common and rare variants might contribute to risk.
Conclusion
We demonstrate that it is possible to implement a test for 
which association can combine information from both 
common and rare variants that has a known distribution 
under the null hypothesis. It is simple to implement, quick 
to perform, and could readily be applied to genome-wide 
sequence data.
Availability
A program implementing the procedure,  named 
 SCOREASSOC, is available as part of the GCPROG  package 
at http://www.mds.qmul.ac.uk/dcurtis/software.html. 
C source code and a Windows executable are provided.
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